Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Tarsus Pharmaceuticals, Inc. (TARS) reported a Q4 loss of $0.60 per share, which was better than the Zacks Consensus Estimate of a $0.68 loss. This is an improvement from the $1.31 loss per share reported a year ago.
February 25, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals reported a Q4 loss of $0.60 per share, beating the Zacks Consensus Estimate of a $0.68 loss. This marks an improvement from the previous year's $1.31 loss per share.
The better-than-expected earnings report, with a smaller loss than estimated, is likely to have a positive short-term impact on Tarsus Pharmaceuticals' stock price. The improvement from the previous year's loss also suggests positive momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100